SSA
LGND icon

Schonfeld Strategic Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,121
Closed -$667K – 2378
2024
Q1 		$667K Buy
+9,121
New +$672K ﹤0.01% 1368
2022
Q4 		– Sell
-5,027
Closed -$270K – 2833
2022
Q3 		$270K Buy
+5,027
New +$296K ﹤0.01% 2150
2019
Q3 		– Sell
-3,241
Closed -$231K – 1136
2019
Q2 		$231K Buy
+3,241
New +$239K 0.01% 850
2019
Q1 		– Sell
-16,030
Closed -$1.36M – 1141
2018
Q4 		$1.36M Buy
16,030
+11,221
+233% +$1.2M 0.05% 400
2018
Q3 		$823K Buy
+4,809
New +$725K 0.04% 470

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Schonfeld Strategic Advisors's LGND Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 9,121 shares — an estimated $667K sold.

Schonfeld Strategic Advisors first reported a position in LGND in Q3 2018 and held it in 5 quarters. The position peaked at $1.36M in Q4 2018. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Schonfeld Strategic Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 9,121 Ligand Pharmaceuticals shares in Q2 2024, an estimated $667K.
  • Schonfeld Strategic Advisors first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Ligand Pharmaceuticals position peaked at $1.36M in Q4 2018.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.